To assess initial results and the safety of stem cell and platelet rich plasma in treatment of chronic obstructive pulmonary disease. Subjects and methods: This interventional trial was carried out on 10 chronic obstructive pulmonary disease patients, with the number of patients of group C and D were 2 and 8, respectively, following to GOLD 2018.
Trang 1
INITIAL RESULTS OF USING MESENCHYMAL STEM CELL
AND PLATELET RICH PLASMA IN TREATMENT
OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Dao Ngoc Bang 1 ; Dong Khac Hung 2 ; Nguyen Huy Luc 1
Do Minh Trung 2 ; Ta Ba Thang 1 ; Le Phuong Ha 3
SUMMARY
Objectives: To assess initial results and the safety of stem cell and platelet rich plasma in treatment of chronic obstructive pulmonary disease Subjects and methods: This interventional
trial was carried out on 10 chronic obstructive pulmonary disease patients, with the number of patients of group C and D were 2 and 8, respectively, following to GOLD 2018 Mesenchymal stem cells were taken from the umbilical cord tissue of pregnant women, were given intravenously to patients with the dose of 1.5 milion cells per kilogram in combination with
5 mililiters of self-platelet rich plasma These patients were followed up within 6 months Results: Clinical and para-clinical indexes improved after 6 months of treatment: mMRC score decreased from 3 to 2, CAT score went from 22 down to 20 and CRP reduced from 5.12 to 2.68 miligram per deciliter There was no severe complication Conclusions: The combination of mesenchymal stem cells and platelet rich plasma is a method with its first effectiveness and safety in treatment of severe chronic obstructive pulmonary disease patients With these initial results, the following studies are expected to carry out to assess the role of mesenchymal stem cells and platelet rich plasma in treatment of chronic obstructive pulmonary disease patients
* Keywords: Chronic obstructive pulmonary disease; Mesenchymal stem cell; Platelet rich plasma
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is now a global burden of disease
with high mortality Many theories about
COPD pathogenesis have been mentioned,
in which the inflammatory mechanism
was recognized by many authors [1, 3]
Till now, many studies have proved that
the effectiveness of mesenchymal stem cells
(MSCs) in treatment of anti-inflammatory
proccess, increase in immune ability and
regeneration of tissue Therefore, MSCs
have been studied in treatment of COPD
in order to improve pulmonary fibrosis, reduction of pulmonary arterial pressure and anti-inflammation Besides, platelet rich plasma (PLT) contains growth factors, helping regeneration of tissue With the combination with PLT, MSCs work effectively [4, 5, 6] In Vietnam, this combination has been firstly applied in treatment of COPD patients By this reason, this study was
carried out with the aim: To assess initial
results and the safety of stem cell and platelet rich plasma in treatment of chronic obstructive pulmonary disease
1 103 Military Hospital
2 Vietnam Military Medical University
3 University of Science and Technology of Hanoi
Corresponding author: Dao Ngoc Bang (bsdaongocbang@yahoo.com.vn)
Dtae received: 29/07/2019
Date accepted: 15/10/2019
Trang 2
SUBJECTS AND METHODS
1 Subjects
10 patients diagnosed with COPD,
having indications of treatment by MSCs
and PLT, treated in Respiratory Center,
103 Military Hospital from Jul 2018 to Apr
2019
* Patient selection criteria: Defined
stable COPD group C and D according to
GOLD standard (2018) [1] These patients
were voluntary to attend in the study
* Patient exclusion criteria: Patients
had other respiratory diseases, severe
co-diseases (such as: heart failure, kidney
failure and so on), other diseases related
to tumour, contrindications of respiratory
functional measurement
2 Methods
* Study design:
This is a clinical non-controlled trial
with vertical follow-up Patients underwent
clinical examination, tests of biochemical
blood and blood cells to assess function
of organs, tumour markers, ECG and
plethymosgraphy, arterial blood gases
test before treatment of MSCs and PLT
Patients underwent treatment by MSCs
and self-PLT based on the process,
accepted by the Ethics Committee of
Vietnam Ministry of Health These patients
were taken sellf-blood to separate PLT
Then, 5 mL of PLT were mixed with MSCs,
taken from the umbilical cord tissue, with
the dose of 1.5 million of MSCs per
kilogram This combination was mixed
with 100 mL of NaCl 0.9% and given
intravenously to patients with the speed
of 3.5 mL per minute Definition of clinical results, blood cells, CRP and changes of respiratory function of these patients
They were re-examined by the time of
1, 3 and 6 months after treament By each time, they were defined: changes of clinical symptoms (level of dyspnea based on mMRC scale, CAT and SMWD), number
of white blood cells with the proportions of neutrophil and lymphocyte, CRP, indexes
of spirometer, such as: force vital capacity (FVC), force expiratory volume in the
1st second (FEV1), arterial blood gases indexes, such as: oxygen arterial preasure (PaO2), carbondioxite arterial preasure (PaCO2)
Early complications (within 1 week) and late ones (within 6 months after treament)
All studied patients underwent internal treatment regularly based on Guidelines
of Vietnam Ministry of Health (2018) [1]
Management and statistical analysis was performed by the SPSS 20.0 software
RESULTS AND DISCUSSION
1 Characteristics of studied patients
* Characteristics of age and gender:
100% of studied patients were male, with the average age of 67.9 ± 6.47 years old and 60% belonged to group of 60 -
70 years old, only 10% of patients at the age under 60 years old These characteristics of age and gender were similar to other studies about COPD in Vietnam Hoaang Dinh Huu Hanh and Le Thi Tuyet Lan (2008) witnessed that the average age of COPD patients was 63 ± 11.97 years old, with 87% belonged to
Trang 3
male [2] However, the number of female
patients was lower than that in other studies
in the world Weiss D.J et al (2013)
treated stem cells for 30 COPD patients, having the average age of 68.1 ± 7.54 years old, with the proportion of 60% [8]
Table 1: Clinical characteristics of studied patients before treatment
Value
The studied patients had high means of CAT and mMRC, short SMWD (278.7 ± 78.37 meters) and high number of exacerbation per year (3.2 ± 1.8 times) These characteristics were similar to other studies about stem cells for COPD patients by Weiss D.J et al (2013), Ribeiro-Paes J.T et al (2011) [8, 9] This is the group of severe patients, with many clinical symptoms and poor response with basic internal treatment However, these studied patients had lower average of BMI when comparing with ones in other studies These characteristics could affect the result of stem cells later
Table 2: Para-clinical characteristics of studied patients before treatment
Value
Blood test:
Spirometer:
Arterial blood gases test:
The studied patients had low average
of FVC and FEV1, corresponding with
65.51 ± 13.5% predicted and 37.88 ±
13.14% predicted About the results of arterial blood gases test, mean of PaO2
was low (76 ± 16.35 mmHg), while mean
Trang 4
of PaCO2 was high (47.1 ± 7.36 mmHg)
These characteristics were suitable with
patient selection criteria for treatment of
stem cells The studied patients in the
research by Weiss D.J et al (2013) had
moderate or severe obstructive degree
[8] The study by Ribeiro-Paes J.T et al
(2011) was also carried out to treat
severe COPD patients by stem cells [9]
The studied patients had WBC at the
normal limitation However, mean of CRP
increased (9.1 ± 10.14 mg/dL) These characteristics were similar to the study
by Weiss D.J et al (2013), with the mean of CRP of studied patients being 7.55 mg/dL [8] Increased CRP showed the status of inflammation and infection
By treatment of stem cells, it could reduce inflammation and inhibit infection Therefore, CRP is also an index to assess the efficacy of stem cell therapy for COPD patients
2 Results of treatment by stem cell and PTL
Table 3: Changes of CAT, SMWD and mMRC after treatment
Changes Indexes
Before treatment (1)
After 3 months (2)
After 6 months (3)
p
(16 - 25)
21 (14 - 24)
20 (12 - 24)
p2,1 > 0.05 p3,1 < 0.05
(128 - 350)
302,5 (155 - 360)
317,5 (160 - 365)
p2,1 > 0.05 p3,1 > 0.05
(3 - 3)
2,5 (2 - 3)
2,5 (2 - 3)
p2,1 < 0.05 p3,1 < 0.05
The results showed that SMWD changed insignificantly CAT and mMRC improved clearly after 6 months, with p < 0.05 These results were similar to other previous published studies about stem cells The study by Ribeiro-Paes J.T et al (2011) witnessed the COPD patients of stage 4 improved significantly their quality of life as well as more stable clinical status [9] Patients in the study by Stolk J et al (2016) also had the improvement of clinical symptoms [10]
Changes Indexes
Before treatment (1)
After 3 months (2)
After 6 months (3)
p
(41.6 - 87)
54.2 (38.6 - 89.5)
60.7 (34.6 - 90.8)
p2,1 > 0.05 p3,1 > 0.05
(16.46 - 64)
31.14 (16.88 - 47.88)
29.45 (14.5 - 64.3)
p2,1 > 0.05 p3,1 > 0.05
(21 - 55)
29.05 (15.8 - 44.1)
31.1 (20.2 - 57.7)
p2,1 > 0.05 p3,1 > 0.05
Trang 5
The studied patients witnessed no
improvement in spirometer indexes
Changes of FVC, FEV1 and PEF were not
statistical (p > 0.05) PaO2 increased
clearly after 6 months (p < 0.05), while
PaCO2 decreased lightly (p > 0.05) SaO2
changed insignificantly after treatment
(p > 0.05) These results were similar to
other previous studies about stem cells
After treatment, COPD patients witnessed
minimal improvement of spirometer
indexes The study by Weiss D.J et al (2013) had the conclusion that there was
no statistical difference of spirometer indexes when comparing the studied group with the control one The results showed that there was no benefit in improvement of respiratory function when treated by stem cells [8] In the study
by Ribeiro-Paes J.T et al (2011), the respiratory indexes had a trend to decline after 30 to 90 days [9]
Table 5: Changes of WBC and CRP after treatment
Changes Indexes
Before treatment (1)
After 3 months (2)
After 6 months (3)
p
(6.2 - 12.56)
7.35 (5.56 - 10.83)
9.38 (5.9 - 14)
p2,1 > 0.05 p3,1 > 0.05
(57.3 - 92.5)
56.74 (48.8 - 69.4)
63.8 (46.81 - 75.32)
p2,1 < 0.05 p3,1 < 0.05
(6.1 - 30.9)
27.85 (17.18 - 34.5)
22.66 (15.99 - 40.32)
p2,1 < 0.05 p3,1 < 0.05
(0.9 - 32.9)
2.26 (0.6 - 18)
2,68 (0.92 - 17.21)
p2,1 < 0.05 p3,1 < 0.05
The studied results showed that CRP reduced statistically at both times of 3 and
6 months after treatment (p < 0.05) The proportion of neutrophil had a trend to go down and lymphocyte go up WBC changed insignificantly The characteristics of reduced CRP were also witnessed in the studies of stem cells, carried out in experimental animals as well as COPD patients The COPD patients in the trial about stem cells by Weiss D.J et al (2013) reduced CRP after 1 month The trend of reduced CRP was witnessed continuously during the time of trial [8]
Chart 1: Changes of arterial blood gases indexes after treatment
PaO2 increased clearly after 6 months (p < 0.05) while PaCO2 decreased lightly (p > 0.05) SaO2 changed insignificantly after treatment (p > 0.05)
Trang 6
3 Complications of treatment by
stem cell and PLT
20% of patients had fever after treatment
of MSCs and 1 patient witnessed a
moderate exacerbation There was no
anaphylaxis, dead or new tumor formation
These results were similar to other previous
studies about stem cells The patients in
the study by Ribeiro-Paes J.T et al (2011)
were followed up within 1 year after
treatment There was no complication [9]
The trial by Weiss et al (2013) also showed
that there was no statistical clinical
adverse event during the follow-up time
after treatment [8] These adverse events
were mild and there was no correlation
found between these ones and treatment
of stem cells This result proved that
treatment of stem cells is a safe method
CONCLUSSIONS
Studying the initial results of MSCs in
combination with PLT in 10 COPD patients,
we had some following conclusions:
- CAT and mMRC improved clearly after
6 months There was no improvement
in spirometer indexes CRP reduced
statistically (p < 0.05) PaO2 increased
clearly after 6 months (p < 0.05) while
PaCO2 decreased lightly (p > 0.05)
- Treatment by stem cells is safe: 20%
of patients had fever and 1 patient had a
moderate exacerbation There was no
anaphylaxis, dead or new tumor formation
REFERENCES
1 Bộ Y tế Quản lý và điều trị BPTNMT
giai đoạn ổn định Hướng dẫn chẩn đoán và
điều trị bệnh phổi tắc nghẽn mạn tính Nhà
xuất bản Y học Hà Nội 2018, tr.22-28
2 Hoàng Đình Hữu Hạnh, Lê Thị Tuyết Lan
Mối liên quan giữa độ khó thở và các chỉ số
hô hấp ký ở bệnh nhân BPTNMT Tạp chí
Y học TP Hồ Chí Minh 2008, 12 (1), tr.96-99
3 Global Intiative for Chronic Obstructive Lung Disease Global strategy for diagnosis,
management and prevention of chronic obstructive pulmonary disease https://goldcopd org/gold-2017-global-strategy-diagnosis-management-prevention-copd.2018
4 Gu W, Song L, Li X-M et al
Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK MAPK pathways Scientific Report 2015, 5 (8733)
5 Isola L.M, Scigliano E, Skerrett D et al
A pilot study of allogeneic bone marrow
Transplant 1997, 20 (12), pp.1033-1037
6 Katsha A.M, Ohkouchi S, Xin H et al
Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model Molecular Therapy 2011,
19 (1), pp.196-203
7 Lee C, Mitsialis S.A, Aslam M et al
Exosomes mediate the cytoprotective action
of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension Circulation
2012, 126 (22), pp.2601-2611
8 Weiss D.J, Casaburi R, Flannery R et al
A placebo-controlled, randomized trial of mesenchymal stem cells in COPD Chest
2013, 143 (6), pp.1590-1598
9 Ribeiro-Paes J.T, Bilaqui A, Greco OT et
al Unicentric study of cell therapy in chronic
obstructive pulmonary disease/pulmonary emphysema International Jounal Chronic Obstructive Pulmonary Disease 2011, 6, pp.63-71
10 Stolk J, Broekman W, Mauad T et al
A phase I study for intravenous autologous mesenchymal stromal cell administration to
International Journal of Medicine 2016, 109 (5), pp.331-333.